Drug Search Results

Duvoglustat

Alternative Names: duvoglustat, at-2220, at2220, at 2220
Latest Update: 2024-04-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GCS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amicus
Company Location: PHILADELPHIA PA 19104
Company CEO: Bradley L. Campbell
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duvoglustat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Glycogen Storage Disease Type II

Trial	Phase	Trial Status	Disease	Primary Completion Date
2013-002257-30	P2	Terminated	Glycogen Storage Disease Type II	2013-12-06
AT2220-010	P2	Completed	Glycogen Storage Disease Type II	2013-01-04
2011-002154-32	P2	Completed	Glycogen Storage Disease Type II	2013-01-04
POM-CL-201	P2	Terminated	Glycogen Storage Disease Type II	2009-12-14

Recent News Events

Date	Type	Title
04/27/2024	PubMed	Modular metabolic engineering of Bacillus amyloliquefaciens for high-level production of green biosurfactant iturin A.
04/24/2024	PubMed	Glucosylceramides impact cellulose deposition and cellulose synthase complex motility in Arabidopsis.
04/24/2024	PubMed	Use of human Caco-2 cells and HPAE-PAD for α-glucosidase assay.
09/15/2022	News Article	Black Men United to Donate Furniture, Household Goods to Ukrainian Refugees in Chicago on Saturday
05/26/2022	News Article	Hodges Ward Elliott Brokers Sale of Hampton Inn Athens
04/21/2022	News Article	Emerging Collective Hosts Panel on Global South Narratives at Dallas Art Fair, Featuring Kenyan Artist Kaloki Nyamai

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions